Chantal Mathieu to Present MELD‑ATG Trial Results at EASD 2025

August 6, 2025
Don’t miss this opportunity to hear the results firsthand and explore the future of type 1 diabetes treatment. Set your alarms and join us in Vienna!
Share this post

We’re proud to announce that dr. Chantal Mathieu will present new data from the MELD‑ATG clinical trial at the upcoming EASD Annual Meeting 2025 in Vienna. Led by KU Leuven and part of the INNODIA consortium, MELD‑ATG is an academic-driven clinical trial exploring an innovative immunotherapy approach to preserve beta cell function and slow disease progression in individuals newly diagnosed with clinical stage 3 type 1 diabetes. Specifically, it investigates the use of low-dose anti-thymocyte globulin (ATG) to modulate the immune response and protect insulin-producing cells.

📅 Date: Friday, 19 September 2025
🕖 Time: 07:15 CEST
📍 Location: Vienna, Austria

📝 Curious? Register now for EASD 2025 and be part of the conversation!

Support us

Choose to make a direct impact by contributing to a specific research project or by supporting the overarching goals of the Hippo & Friends Type 1 Diabetes Fund. 

By donating today, you enable early-career scientists to pursue groundbreaking research aimed at preventing and curing type 1 diabetes.
Every contribution moves us one step closer to breakthroughs that matter.

I want to make a direct donationI want to support Hippo & Friends